Faculty Opinions recommendation of Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Pooled Analysis ◽

Abdominal Fat ◽

Phase 3 ◽

Double Blind ◽

Growth Hormone Releasing Factor ◽

Double Blind Placebo ◽

Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2010-0490 ◽

2010 ◽

Vol 95 (9) ◽

pp. 4291-4304 ◽

Cited By ~ 57

Author(s):

Julian Falutz ◽

Jean-Claude Mamputu ◽

Diane Potvin ◽

Graeme Moyle ◽

Graziella Soulban ◽

...

Keyword(s):

Growth Hormone ◽

Pooled Analysis ◽

Abdominal Fat ◽

Phase 3 ◽

Double Blind ◽

Growth Hormone Releasing Factor ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733042913.793549527 ◽

2018 ◽

Author(s):

David Ginsberg

Keyword(s):

Nasal Spray ◽

Pooled Analysis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial ofd-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment

Journal of NeuroVirology ◽

10.1080/13550280600827344 ◽

2006 ◽

Vol 12 (3) ◽

pp. 178-189 ◽

Cited By ~ 10

Author(s):

Karl Goodkin ◽

Benedetto Vitiello ◽

William D Lyman ◽

Deshratn Asthana ◽

J Hampton Atkinson ◽

...

Keyword(s):

Human Immunodeficiency Virus Type ◽

Virus Type ◽

Controlled Trial ◽

Motor Impairment ◽

Double Blind ◽

Double Blind Placebo ◽

Immunodeficiency Virus ◽

Hiv 1

Double blind, placebo-controlled, randomised clinical trial to evaluate the efficacy of co-trimoxazole given as prophylaxis in reducing mortality in human immunodeficiency virus-infected adults with tuberculosis

http://isrctn.org/> ◽

10.1186/isrctn15281875 ◽

2012 ◽

Author(s):

Alimuddin Zumla

Keyword(s):

Clinical Trial ◽

Randomised Clinical Trial ◽

Double Blind ◽

Double Blind Placebo ◽

An international multi-centre, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of 0.5% and 2% Pro 2000/5 gels for the prevention of vaginally acquired human immunodeficiency virus (HIV) infections

http://isrctn.org/> ◽

10.1186/isrctn64716212 ◽

2012 ◽

Author(s):

Sheena McCormack

Keyword(s):

Controlled Trial ◽

Hiv Infections ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DITIOCARB SODIUM ('IMUTHIOL') IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION

The Lancet ◽

10.1016/s0140-6736(88)90184-5 ◽

1988 ◽

Vol 332 (8613) ◽

pp. 702-706 ◽

Cited By ~ 75

Author(s):

J LANG

Keyword(s):

Virus Infection ◽

Human Immunodeficiency Virus Infection ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.11 ◽

2021 ◽

Vol 5 (1) ◽

pp. s11

Author(s):

Eric Simpson ◽

Joseph Merola ◽

Jonathan Silverberg ◽

Rebecca Zachariae ◽

Rebecca Olsen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pooled Analysis ◽

Adult Patients ◽

Severe Atopic Dermatitis ◽

Phase 2 ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Abstract not available.

Randomised, double-blind, placebo controlled, study to evaluate the safety and efficacy of acetyl L-carnitine (ALCAR), in combination with antiretroviral therapy, for prevention of distal symmetric polyneuropathy (DSP) and lipid abnormalities in treatment of human immunodeficiency virus (HIV)

http://isrctn.org/> ◽

10.1186/isrctn58811572 ◽

2013 ◽

Author(s):

Margaret A Johnson

Keyword(s):

Antiretroviral Therapy ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Immunodeficiency Virus ◽

Distal Symmetric Polyneuropathy ◽

Lipid Abnormalities

A phase II, double blind, placebo controlled, randomised, single centre study to assess the safety, tolerability and acceptability of Dextrin-2 Sulphate gel in sexually active female subjects and their male sexual partners at low risk of Human Immunodeficiency Virus (HIV) infection

http://isrctn.org/> ◽

10.1186/isrctn92729667 ◽

2012 ◽

Author(s):

Naomi Low-Beer

Keyword(s):

Hiv Infection ◽

Sexual Partners ◽

Sexually Active ◽

Single Centre ◽

Double Blind ◽

Double Blind Placebo ◽

Immunodeficiency Virus ◽

Single Centre Study ◽

Male Sexual Partners

A phase II, randomised, double-blind, placebo-controlled pilot study of the safety, tolerability and activity of intramuscularly administered a-Epi-Br (HE2000) in late stage human immunodeficiency virus-infected patients at risk for opportunistic infections

http://isrctn.org/> ◽

10.1186/isrctn81525828 ◽

2013 ◽

Author(s):

Zoja Noveljic

Keyword(s):

At Risk ◽

Pilot Study ◽

Phase Ii ◽

Late Stage ◽

Opportunistic Infections ◽

Double Blind ◽

Double Blind Placebo ◽

Immunodeficiency Virus ◽

Patients At Risk